# Cisplatin + RT for Triple Negative Breast Cancer

> **NCT01674842** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 55 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Radiation Therapy
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01674842
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2018-08
- **Final completion:** 2021-06-08
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01674842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01674842, "Cisplatin + RT for Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01674842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*